ifosfamide has been researched along with Carcinoma, Transitional Cell in 34 studies
Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mesna was administered intravenously at a 20% of the ifosfamide dosage before ifosfamide and orally at 40% after 4 and 8 hours from the ifosfamide infusion." | 6.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
| "The activity of ifosfamide in genitourinary malignancies has been documented in testicular cancer and bladder cancer." | 4.79 | The role of ifosfamide in the treatment of testicular and urothelial malignancies. ( Roth, BJ, 1996) |
| "High-dose ifosfamide (HD-IFX) has shown significant antitumor activity in advanced sarcoma and breast carcinoma." | 3.69 | Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. ( Albanell, J; Baselga, J; Bellmunt, J; Casado, S; Eres, N; Ribas, A, 1997) |
| "Ifosfamide (IFX) is an agent as yet unstudied in advanced urothelial carcinoma." | 2.68 | Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. ( Bono, B; Dreicer, R; Elson, P; Knop, R; Loehrer, PJ; Richardson, RR; Witte, RS, 1997) |
| " Mesna was administered intravenously at a 20% of the ifosfamide dosage before ifosfamide and orally at 40% after 4 and 8 hours from the ifosfamide infusion." | 2.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
| " The aim of this retrospective study was to evaluate the activity and toxicity of bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer." | 1.40 | Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases. ( Li, Y; Shang, YM; Yang, Y; Zheng, H, 2014) |
| "They were 26 bladder cancers and 19 renal cell cancers." | 1.30 | Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological cancers: wide distribution of inhibition rates in bladder cancer and renal cell cancer. ( Fujita, K; Hirano, Y; Suzuki, K; Ushiyama, T, 1999) |
| " (1) The tumor growth was inhibited by CDGP-II in all three different dosage groups (p < 0." | 1.29 | [Evaluation of the chemotherapy of a transplantable bladder tumour strain (NM-B-1) by two anti-cancer drugs in combination with a pressor agent in nude mice]. ( Akima, S; Horiuchi, K; Tsuboi, N; Yoshida, K, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 13 (38.24) | 18.2507 |
| 2000's | 14 (41.18) | 29.6817 |
| 2010's | 5 (14.71) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Hosomi, T | 1 |
| Shibasaki, N | 1 |
| Otsuka, H | 1 |
| Uketa, S | 1 |
| Makino, Y | 1 |
| Shichiri, Y | 1 |
| Li, Y | 1 |
| Yang, Y | 1 |
| Shang, YM | 1 |
| Zheng, H | 1 |
| Gakis, G | 1 |
| Morgan, TM | 1 |
| Daneshmand, S | 1 |
| Keegan, KA | 1 |
| Todenhöfer, T | 1 |
| Mischinger, J | 1 |
| Schubert, T | 1 |
| Zaid, HB | 1 |
| Hrbacek, J | 1 |
| Ali-El-Dein, B | 1 |
| Clayman, RH | 1 |
| Galland, S | 1 |
| Olugbade, K | 1 |
| Rink, M | 1 |
| Fritsche, HM | 1 |
| Burger, M | 1 |
| Chang, SS | 1 |
| Babjuk, M | 1 |
| Thalmann, GN | 1 |
| Stenzl, A | 1 |
| Efstathiou, JA | 1 |
| Kobayashi, K | 1 |
| Matsuyama, H | 1 |
| Shimizu, K | 1 |
| Fujii, N | 1 |
| Inoue, R | 1 |
| Yamamoto, Y | 1 |
| Matsumoto, H | 1 |
| Nagao, K | 1 |
| Lawson, M | 1 |
| Vasilaras, A | 1 |
| De Vries, A | 1 |
| Mactaggart, P | 1 |
| Nicol, D | 1 |
| Milowsky, MI | 1 |
| Nanus, DM | 1 |
| Maluf, FC | 1 |
| Mironov, S | 1 |
| Shi, W | 1 |
| Iasonos, A | 1 |
| Riches, J | 1 |
| Regazzi, A | 1 |
| Bajorin, DF | 5 |
| Kitamura, H | 1 |
| Taguchi, K | 1 |
| Kunishima, Y | 1 |
| Yanase, M | 1 |
| Takahashi, A | 1 |
| Shigyo, M | 1 |
| Tanaka, T | 1 |
| Mutoh, M | 1 |
| Fukuta, F | 1 |
| Masumori, N | 1 |
| Tsukamoto, T | 2 |
| Siefker-Radtke, AO | 1 |
| Dinney, CP | 1 |
| Shen, Y | 1 |
| Williams, DL | 1 |
| Kamat, AM | 1 |
| Grossman, HB | 1 |
| Millikan, RE | 2 |
| Gonzalez-Angulo, AM | 1 |
| Orzano, JA | 1 |
| Davila, E | 1 |
| Maezawa, T | 1 |
| Yonese, J | 2 |
| Ishii, N | 1 |
| Fukui, I | 2 |
| Antonelli, A | 1 |
| Simeone, C | 1 |
| Ferrari, V | 1 |
| Tardanico, R | 1 |
| Cunico, SC | 1 |
| Akima, S | 1 |
| Yoshida, K | 1 |
| Tsuboi, N | 1 |
| Horiuchi, K | 1 |
| Kattan, J | 1 |
| Culine, S | 1 |
| Theodore, C | 1 |
| Droz, JP | 1 |
| Roth, BJ | 3 |
| Dreicer, R | 2 |
| Propert, KJ | 1 |
| Einhorn, LH | 1 |
| Loehrer, PJ | 2 |
| Witte, RS | 1 |
| Elson, P | 1 |
| Bono, B | 1 |
| Knop, R | 1 |
| Richardson, RR | 1 |
| Bellmunt, J | 1 |
| Eres, N | 1 |
| Ribas, A | 1 |
| Casado, S | 1 |
| Albanell, J | 1 |
| Baselga, J | 1 |
| Kyriakakis, Z | 1 |
| Dimopoulos, MA | 1 |
| Kostakopoulos, A | 1 |
| Karayiannis, A | 1 |
| Sofras, F | 1 |
| Zervas, A | 1 |
| Giannopoulos, A | 1 |
| Dimopoulos, C | 1 |
| Pronzato, P | 1 |
| Vigani, A | 1 |
| Pensa, F | 1 |
| Vanoli, M | 1 |
| Tani, F | 1 |
| Vaira, F | 1 |
| Müller, M | 1 |
| Heicappell, R | 1 |
| Steiner, U | 1 |
| Goessl, C | 1 |
| Miller, K | 1 |
| McCaffrey, JA | 3 |
| Hilton, S | 3 |
| Mazumdar, M | 3 |
| Kelly, WK | 3 |
| Scher, HI | 2 |
| Spicer, J | 1 |
| Herr, H | 3 |
| Higgins, G | 2 |
| Kitsukawa, S | 1 |
| Kinn, T | 1 |
| Yoshida, T | 1 |
| Izutami, T | 1 |
| Ishikawa, Y | 1 |
| Sweeney, CJ | 1 |
| Williams, SD | 1 |
| Finch, DE | 1 |
| Bihrle, R | 1 |
| Foster, RS | 1 |
| Collins, M | 1 |
| Fox, S | 1 |
| Hirano, Y | 1 |
| Ushiyama, T | 1 |
| Suzuki, K | 1 |
| Fujita, K | 1 |
| Dodd, PM | 2 |
| Icasiano, E | 2 |
| Boyle, MG | 1 |
| Edelman, MJ | 1 |
| Krege, S | 1 |
| Rembrink, V | 1 |
| Börgermann, C | 1 |
| Otto, T | 1 |
| Rübben, H | 1 |
| Ivanova, R | 1 |
| Veselinova, T | 1 |
| Marinov, E | 1 |
| Ianev, N | 1 |
| Tsvetkov, Ch | 1 |
| Gorchev, G | 1 |
| von der Maase, H | 1 |
| VanderMolen, LA | 1 |
| Sheehy, PF | 1 |
| Dillman, RO | 1 |
| Pagliaro, LC | 1 |
| Tu, SM | 1 |
| Williams, D | 1 |
| Daliani, D | 1 |
| Papandreou, CN | 1 |
| Logothetis, CJ | 1 |
| Yoshimoto, J | 1 |
| Nasu, Y | 1 |
| Akagi, T | 1 |
| Obama, T | 1 |
| Tsushima, T | 1 |
| Ozaki, Y | 1 |
| Matsumura, Y | 1 |
| Ohmori, H | 1 |
| Asahi, T | 1 |
| Ohkita, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Trial of Sequential Doxorubicin/Gemcitabine (AG) and Ifosfamide, Paclitaxel, and Cisplatin (ITP) Chemotherapy (AG-ITP) in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium[NCT00003105] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 1997-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ifosfamide and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Urological implications of cyclophosphamide and ifosfamide.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cyclophosphamide; Cystitis; Humans; Ifosfamide; | 2008 |
The role of ifosfamide in the treatment of testicular and urothelial malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Clinical Trials as Top | 1996 |
[Successful multidisciplinary treatment for bladder cancer with priapism. A case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Comb | 1998 |
New approaches to treatment of metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2000 |
Current and future perspectives in advanced bladder cancer: is there a new standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogeni | 2002 |
15 trials available for ifosfamide and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 2009 |
Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease-F | 2011 |
A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2013 |
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms | 1995 |
Vinblastine, ifosfamide, and gallium nitrate--an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional | 1997 |
Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma, Transitional Cell; Drug Admin | 1997 |
Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic A | 1997 |
Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer.
Topics: Administration, Oral; Aged; Alopecia; Ambulatory Care; Antineoplastic Agents, Alkylating; Bone Marro | 1997 |
Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 1998 |
A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Admi | 1999 |
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
Topics: Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic | 2000 |
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2000 |
Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cyclophosph | 2000 |
Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2001 |
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; | 2002 |
14 other studies available for ifosfamide and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
[Advanced Bladder Cancer with Multiple Pulmonary Metastases Treated with Paclitaxel/Ifosfamide/Nedaplatin Therapy : Two Case Reports].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxy | 2023 |
Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2014 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2016 |
Ifosfamide-induced encephalopathy.
Topics: Antineoplastic Agents, Alkylating; Carcinoma, Transitional Cell; Encephalitis; Humans; Ifosfamide; M | 2002 |
[Combination chemotherapy with ifosfamide, 5-fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy].
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 | 2002 |
Durable and complete remission of a metastatic bladder sarcomatoid carcinoma with chemotherapic and surgical treatments.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinoma, Transitional Cell; | 2006 |
[Evaluation of the chemotherapy of a transplantable bladder tumour strain (NM-B-1) by two anti-cancer drugs in combination with a pressor agent in nude mice].
Topics: Angiotensin II; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cel | 1995 |
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Breast Neoplasms; Carcinoma, Transitional Cell; D | 1997 |
Side effects of chemotherapy for advanced urothelial carcinoma with etoposide and ifosfamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Etoposide; Femal | 1997 |
Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological cancers: wide distribution of inhibition rates in bladder cancer and renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Drug Resistance; Drug Sc | 1999 |
[Malignant Brenner tumor and transitional cell ovarian carcinoma--description of two cases].
Topics: Antineoplastic Agents; Brenner Tumor; Carcinoma, Transitional Cell; Female; Humans; Ifosfamide; Mesn | 2001 |
Successful treatment of transitional cell carcinoma of the urethra with chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Black People; California; Carcinoma, Transitio | 2002 |
[Combination chemotherapy with cisplatin, ifosfamide and adriamycin in patients with advanced transitional cell carcinoma of the urinary tract].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transiti | 1985 |